A detailed history of Rhumbline Advisers transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 124,510 shares of DYN stock, worth $3.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124,510
Previous 121,595 2.4%
Holding current value
$3.65 Million
Previous $4.29 Million 4.22%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$31.94 - $47.04 $93,105 - $137,121
2,915 Added 2.4%
124,510 $4.47 Million
Q2 2024

Aug 01, 2024

BUY
$23.65 - $35.63 $550,240 - $828,967
23,266 Added 23.66%
121,595 $4.29 Million
Q1 2024

May 09, 2024

BUY
$13.06 - $29.18 $288,508 - $644,615
22,091 Added 28.98%
98,329 $2.79 Million
Q4 2023

Feb 08, 2024

BUY
$6.62 - $13.64 $37,515 - $77,297
5,667 Added 8.03%
76,238 $1.01 Million
Q3 2023

Nov 09, 2023

BUY
$8.6 - $12.18 $57,267 - $81,106
6,659 Added 10.42%
70,571 $632,000
Q2 2023

Aug 08, 2023

BUY
$8.53 - $14.28 $108,603 - $181,812
12,732 Added 24.88%
63,912 $719,000
Q1 2023

May 11, 2023

BUY
$10.88 - $15.0 $21,390 - $29,490
1,966 Added 3.99%
51,180 $590,000
Q4 2022

Feb 14, 2023

BUY
$9.37 - $13.8 $3,710 - $5,464
396 Added 0.81%
49,214 $570,000
Q3 2022

Nov 10, 2022

BUY
$7.2 - $15.17 $31,939 - $67,294
4,436 Added 10.0%
48,818 $620,000
Q2 2022

Aug 11, 2022

BUY
$4.36 - $10.5 $30,249 - $72,849
6,938 Added 18.53%
44,382 $305,000
Q1 2022

May 12, 2022

SELL
$6.52 - $12.27 $4,309 - $8,110
-661 Reduced 1.73%
37,444 $361,000
Q4 2021

Feb 10, 2022

SELL
$11.89 - $16.07 $3,388 - $4,579
-285 Reduced 0.74%
38,105 $453,000
Q3 2021

Nov 12, 2021

BUY
$15.6 - $21.46 $21,840 - $30,044
1,400 Added 3.78%
38,390 $623,000
Q2 2021

Aug 05, 2021

BUY
$15.94 - $22.33 $405,545 - $568,119
25,442 Added 220.32%
36,990 $778,000
Q1 2021

May 06, 2021

BUY
$14.0 - $29.3 $161,672 - $338,356
11,548 New
11,548 $179,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.52B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.